For IVD, molecular, lab instrument and digital pathology companies: marketing built on your validation data and written for the lab directors and pathologists who check it.
Senior-led and billed by the hour, with a 30-day cancellation notice. Your first call is with a co-founder.
Lab directors read sensitivity, specificity and the validation cohort first, then turnaround and hands-on time, since most labs run short-staffed. Copy that opens with adjectives loses them before they reach your data.
A test that performs well can still stall if nobody pays for it. Payers, lab benefit managers and hospital finance teams ask what the result changes for the patient and what each result costs, and your marketing has to answer both.
IVDR in Europe and FDA rules in the US limit what you can claim and where. In MedTech Europe's 2024 survey, large IVD makers choosing the EU as their first launch market had dropped by 40% since IVDR, so many companies now plan the two launches separately.
European hospitals buy through tenders scored against criteria set months in advance. If your evidence isn't in the market before the specification is written, your test can be left off the shortlist.
We turn validation studies, method comparisons and workflow data into pages, posters and case studies a lab director can check against the source. Every figure keeps its study reference, so your regulatory team can approve content quickly.
Plans for ADLM, ESCMID Global and USCAP, or the meetings in your specialty: abstracts, booth and symposium content, meetings booked ahead, and KOL sessions recorded for use after the event.
We list the reference labs, hospital groups and lab networks that should be running your test, then reach lab directors, pathologists and procurement with LinkedIn, content and outreach your reps follow up. Coforix, which sells into hospitals, reached 165 high-intent contacts this way.
Product dossiers, evidence summaries, cost-per-result models and reference site lists, prepared before tenders open so your bid team doesn't rebuild them every time.
Pages for the test names, methods and conditions lab staff search for, written so search engines and AI assistants cite your data when someone asks which assay to use.
If your validation data can't support a sentence, the sentence comes out.
Both clients sell to experts who check the evidence before they buy. You'll find every figure in their published case studies.
We don't reuse plans between diagnostics companies. Your Head of Growth writes yours around your test, your evidence and the way labs in your markets buy. The cards show one example: a molecular diagnostics company launching a CE-IVDR-marked panel to hospital labs.
Buyer: lab directors, pathologists and hospital procurement, with payers deciding coverage. Proof: validation data, workflow fit and a reimbursement path.
Diagnostic AI that runs inside a clinical workflow, along with other software and devices used at the point of care, is covered on our MedTech page.
Instruments, reagents and software sold to research labs before any clinical claim are covered on our life science page.
Our health tech report covers how hospital buying committees work and why the evidence bar keeps rising for clinical products.
Amsterdam and New York, for IVD, molecular, lab instrument and digital pathology companies selling in Europe or the US.